CIK 0001840233 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Xilio Therapeutics, Inc.
Sign in to watch- Ticker
- XLO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851623397
- Phone
- 617-833-1027
- Business address
- 828 WINTER STREET, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 8 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-10-26 | SV7 Impact Medicine Fund LP 10% owner | Conversion · Series B Convertible Preferred Stock | −9,486,166 | 0 | ||
| 2021-10-26 | SV7 Impact Medicine Fund LP 10% owner | Conversion · Series B Convertible Preferred Stock | −9,486,166 | 0 | ||
| 2021-10-26 | SV7 Impact Medicine Fund LP 10% owner | Conversion · Series C Convertible Preferred Stock | −2,874,595 | 0 | ||
| 2021-10-26 | SV7 Impact Medicine Fund LP 10% owner | Conversion · Series C Convertible Preferred Stock | −2,874,595 | 0 | ||
| 2021-10-26 | Flynn James E 10% owner | Conversion | +756,472 | 756,472 | ||
| 2021-10-26 | Flynn James E 10% owner | Conversion | +756,472 | 756,472 | ||
| 2021-10-26 | Flynn James E 10% owner | Purchase | +387,500 | $16.00 | $6.2M | 1,143,972 |
| 2021-10-26 | Flynn James E 10% owner | Purchase | +387,500 | $16.00 | $6.2M | 1,143,972 |
| 2021-10-26 | Flynn James E 10% owner | Conversion · Series C Preferred Stock | −7,186,489 | 0 | ||
| 2021-10-26 | Flynn James E 10% owner | Conversion · Series C Preferred Stock | −7,186,489 | 0 | ||
| 2021-10-26 | SV7 Impact Medicine Fund LP 10% owner | Conversion | +998,544 | 998,544 | ||
| 2021-10-26 | SV7 Impact Medicine Fund LP 10% owner | Conversion | +998,544 | 998,544 | ||
| 2021-10-26 | SV7 Impact Medicine Fund LP 10% owner | Conversion | +302,588 | 1,301,132 | ||
| 2021-10-26 | SV7 Impact Medicine Fund LP 10% owner | Conversion | +302,588 | 1,301,132 | ||
| 2021-10-26 | SV7 Impact Medicine Fund LP 10% owner | Conversion · Series B Convertible Preferred Stock | −9,486,166 | 0 | ||
| 2021-10-26 | SV7 Impact Medicine Fund LP 10% owner | Conversion · Series B Convertible Preferred Stock | −9,486,166 | 0 | ||
| 2021-10-26 | SV7 Impact Medicine Fund LP 10% owner | Conversion · Series C Convertible Preferred Stock | −2,874,595 | 0 | ||
| 2021-10-26 | SV7 Impact Medicine Fund LP 10% owner | Conversion · Series C Convertible Preferred Stock | −2,874,595 | 0 | ||
| 2021-10-26 | FIL Ltd See Remark 1 | Conversion | +218,705 | 218,705 | ||
| 2021-10-26 | FIL Ltd See Remark 1 | Conversion · Series B Preferred Stock | −2,077,698 | 0 |
Page 10 of 12 · 224 trades